However, T315I-inclusive compound mutations, defined as a BCR-ABL1 allele with two or more mutations including T315I, have been associated with ponatinib failure in advanced phase CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.